Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment OptionBusiness Wire • 08/22/22
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV CareBusiness Wire • 08/17/22
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia TerritoriesPRNewsWire • 08/15/22
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 StudyBusiness Wire • 08/15/22
Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/02/22